Spots Global Cancer Trial Database for Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Official Title: Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Study ID: NCT05736367

Conditions

Breast Cancer

Interventions

U-13C-glucose

Study Description

Brief Summary: To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.

Detailed Description: Participants will be asked to receive a glucose infusion (U-13C- glucose intravenous) during routine breast cancer surgery at which time, tumor biopsy samples and blood samples will be collected to be used in research experiments to help provide insight into the metabolic activity of the tumor. The length of time on study for each patient will be three - four weeks including two to three hours for glucose infusion and breast cancer biopsy.